Rituximab maintenance significantly prolongs progression-free
survival of patients with newly diagnosed mantle cell lymphoma
treated with the Nordic MCL2 protocol and autologous stem cell
transplantation

J 2019

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation

KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA et. al.

Basic information

Original name

Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation

Authors

KLENER, Pavel (203 Czech Republic, guarantor), David ŠÁLEK (203 Czech Republic, belonging to the institution), Robert PYTLIK (203 Czech Republic), Heidi MOCIKOVA (203 Czech Republic), Kristina FORSTEROVA (203 Czech Republic), Petra BLAHOVCOVA (203 Czech Republic), Vit CAMPR (203 Czech Republic), Vit PROCHAZKA (203 Czech Republic), Ales OBR (203 Czech Republic), Radek JAKSA (203 Czech Republic), Jana KUNTSCHEROVA (203 Czech Republic), Ludmila BOUDOVA (203 Czech Republic), Roman KODET (203 Czech Republic), Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution) and Marek TRNENY (203 Czech Republic)

Edition

American Journal of Hematology, Hoboken, John Wiley & Sons, 2019, 0361-8609

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 6.973

RIV identification code

RIV/00216224:14110/19:00112784

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1002/ajh.25362

UT WoS

000455234700005

Keywords in English

FOLLOW-UP; IMMUNOCHEMOTHERAPY

Abstract

V originále

Mantle cell lymphoma (MCL) is still considered to be an incurable subtype of B-NHL, but the outcome is improving and the implementation of anti-CD20 rituximab and high-dose cytarabine (HDAC) into E50 CORRESPONDENCE induction therapy, consolidation with high-dose therapy and autologous stem cell transplant (ASCT), and rituximab maintenance (RM) are currently considered standard approaches for all transplant-eligible patients. Recently, progression free survival (PFS) and overall survival (OS) benefit of RM were confirmed in patients (pts) with MCL treated with R-DHAP and ASCT.1 Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066), we analyzed outcome of 143 consecutive patients with newly diagnosed MCL treated with the Nordic MCL2 protocol followed by ASCT and RM or observation.2,3 The study was approved by the Ethics Committee of the Charles University General Hospital in Prague under number 1816/15S-IV. Further details are described in the Supplemental Methods.

Citovat

KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA, Petra BLAHOVCOVA, Vit CAMPR, Vit PROCHAZKA, Ales OBR, Radek JAKSA, Jana KUNTSCHEROVA, Ludmila BOUDOVA, Roman KODET, Andrea JANÍKOVÁ and Marek TRNENY. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. American Journal of Hematology. Hoboken: John Wiley & Sons, 2019, vol. 94, No 2, p. "E50"-"E53", 4 pp. ISSN 0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25362.

@article{1612157,
   author = {Klener, Pavel and Šálek, David and Pytlik, Robert and Mocikova, Heidi and Forsterova, Kristina and Blahovcova, Petra and Campr, Vit and Prochazka, Vit and Obr, Ales and Jaksa, Radek and Kuntscherova, Jana and Boudova, Ludmila and Kodet, Roman and Janíková, Andrea and Trneny, Marek},
   article_location = {Hoboken},
   article_number = {2},
   doi = {http://dx.doi.org/10.1002/ajh.25362},
   keywords = {FOLLOW-UP; IMMUNOCHEMOTHERAPY},
   language = {eng},
   issn = {0361-8609},
   journal = {American Journal of Hematology},
   title = {Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation},
   url = {http://dx.doi.org/10.1002/ajh.25362},
   volume = {94},
   year = {2019}
}

TY  - JOUR
ID  - 1612157
AU  - Klener, Pavel - Šálek, David - Pytlik, Robert - Mocikova, Heidi - Forsterova, Kristina - Blahovcova, Petra - Campr, Vit - Prochazka, Vit - Obr, Ales - Jaksa, Radek - Kuntscherova, Jana - Boudova, Ludmila - Kodet, Roman - Janíková, Andrea - Trneny, Marek
PY  - 2019
TI  - Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation
JF  - American Journal of Hematology
VL  - 94
IS  - 2
SP  - "E50"-"E53"
EP  - "E50"-"E53"
PB  - John Wiley & Sons
SN  - 03618609
KW  - FOLLOW-UP
KW  - IMMUNOCHEMOTHERAPY
UR  - http://dx.doi.org/10.1002/ajh.25362
L2  - http://dx.doi.org/10.1002/ajh.25362
N2  - Mantle cell lymphoma (MCL) is still considered to be an incurable subtype of B-NHL, but the outcome is improving and the implementation of anti-CD20 rituximab and high-dose cytarabine (HDAC) into E50 CORRESPONDENCE induction therapy, consolidation with high-dose therapy and autologous stem cell transplant (ASCT), and rituximab maintenance (RM) are currently considered standard approaches for all transplant-eligible patients. Recently, progression free survival (PFS) and overall survival (OS) benefit of RM were confirmed in patients (pts) with MCL treated with R-DHAP and ASCT.1 Whether RM improves outcomes in patients treated with other induction regimens is unknown. As part of the NiHiL observational study in patients with malignant lymphomas (GovTrial No. NCT03199066), we analyzed outcome of 143 consecutive patients with newly diagnosed MCL treated with the Nordic MCL2 protocol followed by ASCT and RM or observation.2,3 The study was approved by the Ethics Committee of the Charles University General Hospital in Prague under number 1816/15S-IV. Further details are described in the Supplemental Methods.
ER  -

KLENER, Pavel, David ŠÁLEK, Robert PYTLIK, Heidi MOCIKOVA, Kristina FORSTEROVA, Petra BLAHOVCOVA, Vit CAMPR, Vit PROCHAZKA, Ales OBR, Radek JAKSA, Jana KUNTSCHEROVA, Ludmila BOUDOVA, Roman KODET, Andrea JANÍKOVÁ and Marek TRNENY. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. \textit{American Journal of Hematology}. Hoboken: John Wiley \&{} Sons, 2019, vol.~94, No~2, p.~''E50''-''E53'', 4 pp. ISSN~0361-8609. Available from: https://dx.doi.org/10.1002/ajh.25362.

Detailed Information on Publication Record